CTAG1A encodes NY-ESO-1, a cancer/testis antigen that serves as a highly immunogenic tumor-associated antigen with restricted expression patterns 1. The protein is primarily expressed in germline cells and various cancers while being absent from most normal tissues, making it an immune-privileged target 1. NY-ESO-1 functions as both a tumor-associated antigen and its own adjuvant, potentially acting as a damage-associated molecular pattern 1. The protein is presented on cell surfaces by major histocompatibility complex class I molecules and elicits strong humoral immune responses, with specific antibody frequencies correlating significantly with disease progression 1. Cancer/testis antigens like NY-ESO-1 are particularly attractive for immunotherapy because male germ cells lack HLA class I molecules, limiting unwanted T-cell responses 2. Clinically, NY-ESO-1 represents a promising target for various immunotherapeutic approaches including cancer vaccines, adoptive T-cell therapies, and TCR-engineered T-cell treatments 12. Autoantibodies against NY-ESO-1 are significantly elevated in patients with metastatic urothelial cancer compared to healthy controls 3. TCR-engineered T-cell therapy targeting NY-ESO-1 has shown objective response rates of 40-60% in clinical trials for advanced cancers 2.